Onco Actu du 8 mars 2018

	3. Prévention
Vitamin D may offer protection against cancers, study says [The Guardian] Experts remain split over whether it is worth taking supplements.
Dose of sunshine exposure could cut the risk of cancer by a fifth [The Telegraph] A study of 34,000 adults found those with high levels of Vitamin D had a 20 per cent lower chance of cancer. Although the vitamin is found in some foods, including oily fish, eggs and fortified cereals, as well as in supplements, the main source is sunshine.
	3.6 Prévention - Activité physique
Testing an Interactive Approach to Promote Exercise in Young Cancer Survivors [NCI] For participants in the intervention group, the amount of moderate to vigorous physical activity increased by an average of nearly 5 minutes a week over the course of the study, whereas for participants in the control group it decreased by an average of more than 24 minutes a week.
	4. Dépistage, diagnostic et pronostic
Imaging agent helps predict success of lung cancer therapy [Stanford Medicine] With the help of a new radioactive tracer, doctors can predict with more than 80 percent accuracy how well a widely-used lung cancer drug will combat tumors, according to researchers at Stanford.
Cancer screening recommendations: an international comparison of high income countries [Public Health Reviews] The goal of this study was to summarize the cancer screening recommendations from the 21 countries with the highest per capita spending on healthcare.
	4.1 Dép., diag. & prono. - Prostate
Myriad Applauds AACU Position Statement on Molecular Testing for Risk Stratification in Prostate Cancer [Myriad] Position Statement Also Supports Access to Hereditary Cancer Testing for Prostate Cancer.
	4.9 Dép., diag. & prono. - Sein
Breast cancer screening guidelines may lead to delayed diagnosis in nonwhite women [Mass. General Hospital] The current guidelines for mammographic breast cancer screening, which are based on data from primarily white populations, may lead to delayed diagnosis in nonwhite women, according to a report published in JAMA Surgery.
	5.12.1 Immunothérapies - partenariats
Eisai Co., Ltd. and Merck Enter Global Strategic Oncology Collaboration for LENVIMA® (lenvatinib mesylate) [Merck] Companies to Jointly Develop and Commercialize LENVIMA, as Monotherapy and in Combination with Merck’s KEYTRUDA ® (pembrolizumab) for Multiple Cancer Types.
Doubling down on the Keytruda franchise, Merck pays $300M and promises $5B-plus to partner with Eisai on its budding cancer star [EndPoints] Merck sees a big future for this drug (lenvatinib mesylate) tied to Keytruda, which is now involved in more than 700 clinical trials.
Eisai clinches Merck deal to develop and sell cancer drug, shares soar [Reuters] The deal, under which Lenvima will be developed for several types of cancer alone and in combination with Merck’s immunotherapy Keytruda, could be worth up to $5.76 billion to Eisai, but most of that would be contingent on eventual sales.
	5.12.2 Immunothérapies - CAR-T
MD Anderson and Berkeley Lights launch Optera Therapeutics to accelerate development of cell therapies for cancer [MD Anderson] Optera Therapeutics will develop cancer cell therapies discovered at MD Anderson and apply Berkeley Lights’ advanced cell therapy manufacturing systems with the goal of making these novel therapies accessible to all.
	5.2 Pharma
Roche promotes Pao to replace departing pRED head Reed [FierceBiotech] Pao’s last stops before joining Roche were the personalized cancer medicine unit of Vanderbilt-Ingram Cancer Center and the oncology department of Vanderbilt University.
Changes to the Roche Enlarged Corporate Executive Committee [Roche] William Pao (1967), MD, PhD, currently Global Head of the Oncology Discovery and Translational Area for pRED, has been appointed the new Head of Roche pRED and will become a member of the enlarged Corporate Executive Committee.
	5.2.1 Pharma - Partenariats
Aptose signs $125M-plus BET inhibitor deal with Ohm Oncology [FierceBiotech] Aptose and Ohm have effectively been working together on BET/kinase, alongside scientists at Florida’s Moffitt Cancer Center, since 2015.
Pfizer breaks off a 5-year, $635M collaboration deal with CytomX, with nothing to show for it [EndPoints] The South San Francisco-based biotech says that Pfizer notified them yesterday that they are dropping out of the Probody deal, discarding its latest two targets after dumping the first on EGFR and never going after the fourth. Pfizer was looking for safer versions of Erbitux and Vectibix.
	5.4 Traitements - Economie
Cancer treatment guidelines questioned in new study [CNN] First, "the people who are making these decisions about treatment are often times people who are consultants and paid by the drug companies that benefit from these recommendations," Brawley said, adding that the American Cancer Society doesn't make recommendations regarding treatments due to that risk of potential conflicts.
Vinay Prasad on the NCCN’s cancer treatment guidelines: The US system needs an audit [BMJ Blogs] What level of evidence should we have before costly, toxic cancer drugs are given to patients?
US cancer network recommending expensive drugs based on weak evidence, study finds [The Guardian] Prasad’s study focused on 47 new drugs approved by the FDA between 2011 and 2015. The FDA approved those drugs for 69 different indications. However, the NCCN recommended those drugs for 113 indications, 44 more indications than the FDA approved.
Capturing the Benefits of Competition for Patients [FDA] I want to focus my remarks today on access to generic and other follow-on medicines and, in particular, on the market for biosimilars – or follow on versions of branded, innovator biologics.
FDA head Gottlieb criticizes industry for 'Kabuki drug-pricing' [Reuters] Gottlieb delivered the remarks at an annual conference of health insurers in a speech largely aimed at promoting biosimilars, rival treatments that are as effective as the original but cheaper.
	6. Lutte contre les cancers
Tumors and Transformations [NEJM] To cope, I occupied my time and mind with exercise, work, and tasks while the sadness of these cases dissolved somewhere inside. But for the father and son with cancer, there was no room, no space within me. In the days following my experience with the patient, I tried to persist and press on, but I had entered an unknown world, one that I did not understand.
	6.10.1 Politiques (USA)
How the ‘right-to-try’ movement muscled its way into Washington [STAT] In September 2012, a group of executives from the Cancer Treatment Centers of America reached out to the Goldwater Institute, a small, libertarian think tank named for the former senator and presidential candidate.
	6.3 Associations/Fondations
Pharma backing of advocacy groups: a call for transparency [HealthNewsReview] Many of the pharmaceutical companies listed in the report counter that they’ve acted within the law. Many advocacy groups have nonprofit status and are not required to report donations.
	6.7 DMP, Big Data & applis
ASCO Launches New Website Focused on the Business of Oncology [ASCO in Action] ASCO Practice Central provides a one-stop, centralized resource that oncology practices can use to address a wide range of practical issues, including changes to physician reimbursement, quality reporting requirements, and business management practices.